Men being treated for prostate cancer feel more optimistic about their condition over time, reflecting their positive experience of treatment and the high level of trust they have in their specialist physician, according to results from a global survey1 providing unique insight into men’s experience of this common cancer.
Research led by Cold Spring Harbor Laboratory (CSHL) may link viruses that have been considered harmless to chromosomal instability (CIN) and cancer.
Researchers at The Hospital for Sick Children (SickKids) have found that taking prenatal multivitamins fortified with folic acid can reduce the risk of three common childhood cancers: leukemia, brain tumours and neuroblastoma. This research was published online on February 21, 2007, in the journal Clinical Pharmacology & Therapeutics.
Why are African American women 1.5 to 2.2 times more likely than White women to die from breast cancer, despite their lower incidence of the disease?
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
Researchers suggest a reason for racial disparity in breast cancer survival rates. African and African American women are much less likely to survive breast cancer surgery than their white counterparts and far more likely to get the disease before the menopause. Previous research suggests that those who undergo surgery for the disease before the menopause are more prone to relapse.
Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk of the disease, according to two randomized, blinded clinical trials in the February 21 Journal of the National Cancer Institute. The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer.
When cells become cancerous, they also become 100 times more likely to genetically mutate than regular cells, researchers have found. The findings may explain why cells in a tumor have so many genetic mutations, but could also be bad news for cancer treatments that target a particular gene controlling cancer malignancy.
New results in the field of RNA research establish that the RNA splicing factor SF2/ASF can act as a cancer-causing protein by changing the alternative splicing of other genes critical for growth-control of cells.